Patents by Inventor Samuel E. Metobo
Samuel E. Metobo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260124198Abstract: The disclosure provides compounds of Formulae (I) or (II), or a pharmaceutically acceptable salt thereof, (I), or (II) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.Type: ApplicationFiled: February 13, 2023Publication date: May 7, 2026Inventors: Evangelos AKTOUDIANAKIS, Britton K. CORKEY, Jenna M. FRANKE, Isabella f. GERMEK, Jason R. HUDLICKY, Rao V. KALLA, Peichao LU, Erik P. MCAULEY, Samuel E. METOBO, Robert Joseph MOREAU, Thao D. PERRY, Naomi RAJAPAKSA, David Charles TULLY, Joseph Michael YOUNG, Qian ZHAO
-
Patent number: 12590062Abstract: Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.Type: GrantFiled: November 13, 2020Date of Patent: March 31, 2026Assignee: Gilead Sciences, Inc.Inventors: Evangelos Aktoudianakis, Todd Appleby, Aesop Cho, Zhimin Du, Michael Graupe, Juan A. Guerrero, Salman Y. Jabri, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Gregory Notte, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
-
Publication number: 20250353820Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.Type: ApplicationFiled: May 9, 2025Publication date: November 20, 2025Applicants: Novartis AG, Gilead Sciences, Inc.Inventors: Zef KONST, Yipin LU, Robert Joseph MOREAU, Naomi Samadara RAJAPAKSA, Galen SHEARN-NANCE, David Charles TULLY, Michael Robert TURNER, Joseph Michael YOUNG, Qian ZHAO, Britton K. CORKEY, Samuel E. METOBO
-
Publication number: 20250270195Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.Type: ApplicationFiled: May 13, 2025Publication date: August 28, 2025Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Wathins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
-
Patent number: 12377100Abstract: The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.Type: GrantFiled: December 2, 2021Date of Patent: August 5, 2025Assignee: Gilead Sciences, Inc.Inventors: Evangelos Aktoudianakis, Gregory Chin, Richard L. Mackman, Samuel E. Metobo, Michael R. Mish, Hyung-Jung Pyun, Jeff Zablocki
-
Patent number: 12338233Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.Type: GrantFiled: December 1, 2022Date of Patent: June 24, 2025Assignee: Gilead Sciences, Inc.Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
-
Patent number: 12338220Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.Type: GrantFiled: February 6, 2023Date of Patent: June 24, 2025Assignees: GILEAD SCIENCES, INC., NOVARTIS AGInventors: Zef Konst, Yipin Lu, Robert Joseph Moreau, Naomi Samadara Rajapaksa, Galen Shearn-Nance, David Charles Tully, Michael Robert Turner, Joseph Michael Young, Qian Zhao, Britton K. Corkey, Samuel E. Metobo
-
Patent number: 12269812Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.Type: GrantFiled: July 8, 2020Date of Patent: April 8, 2025Assignee: Gilead Sciences, Inc.Inventors: Evangelos Aktoudianakis, Aesop Cho, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Devan Naduthambi, Barton W. Phillips, Scott Preston Simonovich, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
-
Patent number: 12037342Abstract: The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: GrantFiled: August 17, 2022Date of Patent: July 16, 2024Assignee: Gilead Sciences, Inc.Inventors: Evangelos Aktoudianakis, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Kristyna M. Elbel, Rao V. Kalla, Samuel E. Metobo, Scott A. Mitchell, Thao D. Perry, Scott P. Simonovich, Christopher A. Ziebenhaus
-
Publication number: 20230365511Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.Type: ApplicationFiled: February 6, 2023Publication date: November 16, 2023Applicants: Novartis AG, Gilead Sciences, Inc.Inventors: Zef Konst, Yipin Lu, Robert Joseph Moreau, Naomi Samadara Rajapaksa, Galen Shearn-Nance, David Charles Tully, Michael Robert Turner, Joseph Michael Young, Qian Zhao, Britton K. Corkey, Samuel E. Metobo
-
Publication number: 20230212155Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.Type: ApplicationFiled: December 1, 2022Publication date: July 6, 2023Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
-
Publication number: 20230183262Abstract: The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: ApplicationFiled: August 17, 2022Publication date: June 15, 2023Inventors: Evangelos Aktoudianakis, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Kristyna M. Elbel, Rao V. Kalla, Samuel E. Metobo, Scott A. Mitchell, Thao D. Perry, Scott P. Simonovich, Christopher A. Ziebenhaus
-
Patent number: 11667613Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.Type: GrantFiled: September 24, 2020Date of Patent: June 6, 2023Assignees: Novartis AG, Gilead Sciences, Inc.Inventors: Zef Konst, Yipin Lu, Robert Joseph Moreau, Naomi Samadara Rajapaksa, Galen Shearn-Nance, David Charles Tully, Michael Robert Turner, Joseph Michael Young, Qian Zhao, Britton K. Corkey, Samuel E. Metobo
-
Patent number: 11555029Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.Type: GrantFiled: June 3, 2020Date of Patent: January 17, 2023Assignee: Gilead Sciences, Inc.Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
-
Patent number: 11453681Abstract: The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.Type: GrantFiled: May 21, 2020Date of Patent: September 27, 2022Assignee: Gilead Sciences, Inc.Inventors: Evangelos Aktoudianakis, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Kristyna M. Elbel, Rao V. Kalla, Samuel E. Metobo, Scott A. Mitchell, Thao D. Perry, Scott P. Simonovich, Christopher A. Ziebenhaus
-
Publication number: 20220218709Abstract: The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.Type: ApplicationFiled: December 2, 2021Publication date: July 14, 2022Inventors: Evangelos Aktoudianakis, Gregory Chin, Richard L. Mackman, Samuel E. Metobo, Michael R. Mish, Hyung-Jung Pyun, Jeff Zablocki
-
Patent number: 11236085Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.Type: GrantFiled: October 22, 2019Date of Patent: February 1, 2022Assignee: Gilead Sciences, Inc.Inventors: Zhimin Du, Michael Graupe, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Eric Q. Parkhill, Barton W. Phillips, Scott P. Simonovich, Peiyuan Wang, Jie Xu, Christopher A. Ziebenhaus
-
Publication number: 20210403497Abstract: Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,2-f][1,2,4]triazinyl heterocycles of Formula I.Type: ApplicationFiled: March 23, 2021Publication date: December 30, 2021Inventors: Thomas Butler, Aesop Cho, Benjamin R. Graetz, Choung U. Kim, Samuel E. Metobo, Oliver L. Saunders, Andrew W. Waltman, Jie Xu, Lijun Zhang
-
Publication number: 20210323922Abstract: Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.Type: ApplicationFiled: November 13, 2020Publication date: October 21, 2021Applicant: Gilead Sciences, Inc.Inventors: Evangelos Aktoudianakis, Todd Appleby, Aesop Cho, Zhimin Du, Michael Graupe, Juan A. Guerrero, Salman Y. Jabri, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Gregory Notte, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
-
Publication number: 20210130302Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.Type: ApplicationFiled: September 24, 2020Publication date: May 6, 2021Inventors: Zef KONST, Yipin LU, Robert Joseph MOREAU, Naomi Samadara RAJAPAKSA, Galen SHEARN-NANCE, David Charles TULLY, Michael Robert TURNER, Joseph Michael YOUNG, Qian ZHAO, Britton K. CORKEY, Samuel E. METOBO